BNP Paribas Financial Markets’s Cyclerion Therapeutics CYCN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8 Hold
5
﹤0.01% 5770
2025
Q4
$6 Hold
5
﹤0.01% 5702
2025
Q3
$12 Hold
5
﹤0.01% 5516
2025
Q2
$15 Hold
5
﹤0.01% 5400
2025
Q1
$12 Hold
5
﹤0.01% 5333
2024
Q4
$16 Buy
+5
New +$14 ﹤0.01% 5354
2023
Q2
Sell
-5
Closed -$39 3934
2023
Q1
$39 Sell
5
-11
-69% -$139 ﹤0.01% 3801
2022
Q4
$208 Hold
16
﹤0.01% 3923
2022
Q3
$273 Hold
16
﹤0.01% 4584
2022
Q2
$174 Buy
16
+2
+14% +$29 ﹤0.01% 4003
2022
Q1
$319 Hold
14
﹤0.01% 4056
2021
Q4
$494 Hold
14
﹤0.01% 4113
2021
Q3
$881 Buy
14
+3
+27% +$196 ﹤0.01% 3883
2021
Q2
$881 Sell
11
-396
-97% -$24.8K ﹤0.01% 3953
2021
Q1
$22.7K Buy
407
+184
+83% +$13.8K ﹤0.01% 3737
2020
Q4
$13.7K Sell
223
-38
-15% -$2.59K ﹤0.01% 3899
2020
Q3
$31.8K Buy
261
+196
+302% +$22.4K ﹤0.01% 3665
2020
Q2
$7.72K Sell
65
-307
-83% -$25.7K ﹤0.01% 3821
2020
Q1
$19.7K Buy
372
+192
+107% +$13.7K ﹤0.01% 3915
2019
Q4
$9.82K Buy
180
+36
+25% +$3.36K ﹤0.01% 4127
2019
Q3
$34.8K Buy
144
+53
+58% +$11.4K ﹤0.01% 3679
2019
Q2
$20.8K Buy
+91
New +$25.8K ﹤0.01% 3880

Other funds holding CYCN

BNP Paribas Financial Markets's CYCN Position: Q1 2026 in Review

BNP Paribas Financial Markets held its Cyclerion Therapeutics (CYCN) position steady in Q1 2026 at 5 shares worth $8. The position accounts for ﹤0.01% of the portfolio, ranked #5770.

BNP Paribas Financial Markets first reported a position in CYCN in Q2 2019 and has held it in 22 quarters since. The position peaked at $34.8K in Q3 2019. 17 funds tracked by Wall St. Rank hold CYCN as of Q1 2026.

  • BNP Paribas Financial Markets held 5 shares of Cyclerion Therapeutics worth $8 as of Q1 2026.
  • BNP Paribas Financial Markets left its Cyclerion Therapeutics share count unchanged in Q1 2026.
  • Cyclerion Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5770 holding.
  • BNP Paribas Financial Markets first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 22 quarters since.
  • BNP Paribas Financial Markets's Cyclerion Therapeutics position peaked at $34.8K in Q3 2019.
  • 17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.